Lambert DM, Fowler CJ (2005). «The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications». J. Med. Chem.48 (16): 5059-87. PMID16078824. doi:10.1021/jm058183t.
Morgan CJ, Curran HV (abril de 2008). «Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis». The British journal of psychiatry : the journal of mental science192 (4): 306-7. PMID18378995. doi:10.1192/bjp.bp.107.046649.
Mahadevan A, Siegel C, Martin BR, Abood ME, Beletskaya I, Razdan RK (octubre de 2000). «Novel cannabinol probes for CB1 and CB2 cannabinoid receptors». Journal of medicinal chemistry43 (20): 3778-85. PMID11020293. doi:10.1021/jm0001572.
Hanuš L, Abu-Lafi S, Fride E, et al. (2001). «2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor». Proc. Natl. Acad. Sci. U.S.A.98 (7): 3662-5. PMID11259648. doi:10.1073/pnas.061029898.
Ralevic V. (julio de 2003). «Cannabinoid modulation of peripheral autonomic and sensory neurotransmission.». European journal of pharmacology472 (1-2): 1-21. PMID12860468. doi:10.1016/S0014-2999(03)01813-2.
Lambert DM, Fowler CJ (2005). «The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications». J. Med. Chem.48 (16): 5059-87. PMID16078824. doi:10.1021/jm058183t.
Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos G (2005). «Evidence for novel cannabinoid receptors». Pharmacol. Ther.106 (2): 133-45. PMID15866316. doi:10.1016/j.pharmthera.2004.11.005.
Morgan CJ, Curran HV (abril de 2008). «Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis». The British journal of psychiatry : the journal of mental science192 (4): 306-7. PMID18378995. doi:10.1192/bjp.bp.107.046649.
Mahadevan A, Siegel C, Martin BR, Abood ME, Beletskaya I, Razdan RK (octubre de 2000). «Novel cannabinol probes for CB1 and CB2 cannabinoid receptors». Journal of medicinal chemistry43 (20): 3778-85. PMID11020293. doi:10.1021/jm0001572.
Grotenhermen F. "Cannabinoids." Current Drug Targets - CNS & Neurological Disorders. 2005 Oct;4(5):507-30. PMID 16266285
Stella N, Schweitzer P, Piomelli D. "A second endogenous cannabinoid that modulates long-term potentiation." Nature. 1997 Aug 21; 388(6644):773-8. PMID 9285589
reviewed in Pacher P, Batkai S, Kunos G. "The endocannabinoid system as an emerging target of pharmacotherapy." Pharmacological Reviews. 2006 Sep;58(3):389-462. PMID 16968947
Savinainen JR, Jarvinen T, Laine K, Laitinen JT. "Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes." British Journal of Pharmacology. 2001 Oct; 134(3):664-72. PMID 11588122
Hanuš L, Abu-Lafi S, Fride E, et al. (2001). «2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor». Proc. Natl. Acad. Sci. U.S.A.98 (7): 3662-5. PMID11259648. doi:10.1073/pnas.061029898.
Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, Waku K, Sugiura T. "Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species." Journal of Neurochemistry. 2003 Jun;85(6):1374-81. PMID 12787057
Bisogno, T., D. Melck, M. Bobrov, N. M. Gretskaya, V. V. Bezuglov, L. De Petrocellis, V. Di Marzo. "N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo." The Biochemical Journal. 2000 Nov 1;351 Pt 3:817-24. PMID 11042139
Bisogno T, Ligresti A, Di Marzo V. "The endocannabinoid signalling system: biochemical aspects." Pharmacology, Biochemistry, and Behavior. 2005 Jun;81(2):224-38. PMID 15935454
Ralevic V. (julio de 2003). «Cannabinoid modulation of peripheral autonomic and sensory neurotransmission.». European journal of pharmacology472 (1-2): 1-21. PMID12860468. doi:10.1016/S0014-2999(03)01813-2.
